Abstract
Straub-tail behavior was induced by subcutaneous injection of different doses (10-60 mg/kg) of morphine to mice. The maximum response was obtained with 20-40 mg/kg of the drug. The response induced by morphine (40 mg/kg) was decreased by intraperitoneal administration of different doses of clonidine (0.05-0.1 mg/kg). Pretreatment of animals with yohimbine (1-4 mg/kg i.p.) reversed the inhibitory action of clonidine. Yohimbine did not elicit any response by itself. Administration of prazosin (0.25, 0.5, and 1 mg/kg) reduced the morphine response. The combination of prazosin with yohimbine (1 mg/kg), but not with clonidine (0.05 mg/kg), caused a potentiated inhibition of the morphine effect. Phenylephrine (2-6 mg/kg i.p.) did not elicit any effect by itself and also did not alter the response induced by morphine or morphine plus clonidine. Dobutamine (2.5-10 mg/kg i.p.), atenolol (2.5-10 mg/kg i.p.), salbutamol (2.5-10 mg/kg i.p.), and propranolol (2.5-10 mg/kg i.p.) did not alter morphine-induced Straub-tail behavior in mice. In conclusion, activation of alpha2-adrenergic pathways contributes to morphine-induced Straub tail, while alpha1- and beta2-adrenergic may not be involved in this phenomenon.
References
Apr 1, 1978·Japanese Journal of Pharmacology·T KameyamaT Nabeshima
Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·B L KiefferC G Hirth
Dec 28, 1992·Science·C J EvansR H Edwards
Jul 1, 1992·Neuroscience·A TaniK Mori
Aug 10, 1990·European Journal of Pharmacology·Y HasegawaS Otomo
Nov 13, 1990·European Journal of Pharmacology·Y HasegawaS Otomo
Jan 1, 1990·Psychopharmacology·C W Murray, A Cowan
Feb 1, 1989·Trends in Pharmacological Sciences·J Traynor
May 1, 1989·British Journal of Pharmacology·A AdellG Curzon
May 26, 1986·Life Sciences·G W Pasternak, P J Wood
Oct 1, 1987·Pharmacology, Biochemistry, and Behavior·T P JerussiM J Benvenga
Jan 1, 1988·Psychopharmacology·P E MannR J Bodnar
Jun 1, 1969·British Journal of Pharmacology·M D AcetoJ Pearl
May 2, 1980·Science·G W PasternakS H Snyder
Oct 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·B L Wolozin, G W Pasternak
Jun 14, 1982·Life Sciences·H Blumberg, D M Slovak
May 1, 1995·Neuroscience·R W GearJ D Levine
Jan 9, 1995·Brain Research·M B WeingerN T Smith
Jan 5, 1995·European Journal of Pharmacology·D Paul, J G Tran
Sep 22, 1994·European Journal of Pharmacology·C NathK N Dhawan
Jan 1, 1993·Psychopharmacology·M NaritaH Nagase
Jan 1, 1993·General Pharmacology·M R ZarrindastB Shafaghi
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·K YasudaG I Bell
Dec 1, 1960·British Journal of Pharmacology and Chemotherapy·D L BilbeyM H Grossman
Jan 1, 1994·Journal of Psychopharmacology·M R ZarrindastM Ghazi Khansari
Citations
Nov 13, 2003·Peptides·Richard J Bodnar, Maria M Hadjimarkou
Dec 2, 2010·The Journal of Pharmacology and Experimental Therapeutics·John J LoweryEdward J Bilsky
Oct 30, 2016·European Journal of Pharmacology·Irina V BelozertsevaAnton Yu Bespalov
Feb 6, 2016·PloS One·Tiina KeränenRiku Korhonen
Mar 28, 2008·The Journal of Pharmacology and Experimental Therapeutics·Nicolas P LapointePierre A Guertin
Jun 27, 2019·American Journal of Physiology. Lung Cellular and Molecular Physiology·Olivia Rose StephensSerpil C Erzurum